This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Male Breast Cancer Treatment
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Breast Cancer Treatment
Treatment of recurrent breast cancer (cancer that has come back after treatment) in the breast or chest wall may include the following:Surgery (modified radical mastectomy), radiation therapy, or both.Chemotherapy or hormone therapy.Antibody-drug conjugate therapy with ado-trastuzumab emtansine.A clinical trial of trastuzumab combined with chemotherapy.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent breast cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.High-Penetrance Breast and/or Ovarian Cancer Susceptibility GenesAdded text about a study of 746 Hispanic patients with a personal or family history of breast cancer and/or ovarian cancer who were examined for the prevalence of BRCA1 and BRCA2 mutations. Deleterious BRCA mutations were identified in 25% of the patients, and a possible founder mutation (BRCA1 ex9-12del) was identified (cited Weitzel et al. as reference 67). Also added text about a population-based cohort of 492 Hispanic women with breast cancer that suggested that the BRCA1 ex9-12 deletion may be a Mexican founder mutation and may represent 10% to 12% of all BRCA1 mutations in similar clinic- and population-based cohorts in the United States. This summary is written and maintained by the PDQ Cancer Genetics Editorial Board,
BRCA1andBRCA2IntroductionEpidemiologic studies have clearly established the role of family history as an important risk factor for both breast and ovarian cancer. After gender and age, a positive family history is the strongest known predictive risk factor for breast cancer. However, it has long been recognized that in some families, there is hereditary breast cancer, which is characterized by an early age of onset, bilaterality, and the presence of breast cancer in multiple generations in an apparent autosomal dominant pattern of transmission (through either the maternal or paternal lineage), sometimes including tumors of other
For men with locally recurrent disease (cancer that has come back in a limited area after treatment), treatment is usually either:Surgery combined with chemotherapy; orRadiation therapy combined with chemotherapy.
General Information Many of the medical and scientific terms used in this summary are found in the NCI Dictionary of Genetics Terms. When a linked term is clicked,the definition will appear in a separate window. Among women,breast cancer is the most commonly diagnosed cancer after nonmelanoma skin cancer,and is the second leading cause of cancer deaths after lung cancer. In 2008,an ...
Breast cancer is a disease in which malignant (cancer) cells form in the tissues of the breast. The breast is made up of lobes and ducts. Each breast has 15 to 20 sections called lobes,which have many smaller sections called lobules. The lobes and lobules are connected by thin tubes called ducts. Anatomy of the breast,showing lymph nodes and lymph vessels. Each breast also contains blood ...